Plastic surgeons throughout the United States are injecting patients with highly processed adipose tissue harvested from deceased donors to add volume to buttocks, hips, breasts, and other areas. The product, known as alloClae and developed by Tiger Aesthetics, offers an off-the-shelf alternative to traditional fat grafting, eliminating the need for liposuction in patients. A viral video from prominent New York City surgeon Dr. Lara Devgan explaining its benefits has thrust this treatment into the spotlight, prompting both enthusiasm from providers and widespread public unease.
alloClae consists of sterilized human adipose tissue sourced from consented cadaver donors through FDA-regulated tissue banks and recovery agencies. The material undergoes a proprietary multi-step processing protocol that includes detergent washes and gamma radiation to remove all DNA, living cells, cellular debris, and immunogenic components while preserving the natural extracellular matrix, collagen, growth factors, and proteins. In its final form, the filler is typically composed of a structural matrix, with some descriptions noting that around 60 percent of the material is intact adipocytes and 40 percent is a supportive scaffold, packaged in ready-to-use syringes with volumes ranging from 12.5 cc to 25 cc.
This rigorous processing ensures the product meets strict safety standards as a Human Cells, Tissues, and Cellular and Tissue-Based Product under FDA oversight, with donors undergoing comprehensive screening for infectious diseases. Once injected, alloClae integrates with the patient’s own tissue, reportedly achieving 75 to 100 percent viability as the body’s cells populate the donor matrix, resulting in long-lasting, natural-feeling results. Clinics nationwide now utilize it for Brazilian butt lifts without surgery, hip dip correction, cellulite smoothing, breast enhancement, hand rejuvenation, and volume restoration in patients who have experienced rapid weight loss.
The treatment gained explosive attention after Dr. Devgan’s clip circulated widely in early January 2026, where she described alloClae as an exciting option for thin patients or those who previously lacked sufficient fat for autologous transfers. Providers emphasize its convenience, reduced procedure time, and superior graft survival compared to traditional methods, which often result in only 50 percent retention. Early adopters report high satisfaction, particularly for minimally invasive body contouring in an era of widespread weight-loss drug use, leaving many seeking non-surgical volume replacement.
Public response has been sharply divided, with many expressing visceral discomfort at injecting material derived from human remains, even after extensive purification and consent protocols. Social media reactions range from horror and ethical concerns about commodifying cadavers to dark humor about intimacy with “donor fat.” These debates highlight ongoing tensions in regenerative medicine, where techniques proven in reconstructive surgery are now being applied to elective aesthetics.
alloClae represents a significant advancement in regenerative aesthetics, building on established tissue grafting principles while addressing limitations of patient-sourced fat. Its rise underscores surging demand for natural, durable enhancements without implants or extensive surgery. Yet the controversy serves as a reminder that medical innovation frequently challenges societal boundaries around the human body and what constitutes acceptable sources for beauty treatments.
For official product details, please visit the manufacturer’s website at Tiger Aesthetics. A comprehensive explainer with before-and-after insights is available here on Allure. Dr. Lara Devgan’s practice can be found on her website. Clinics that provide a detailed description of the procedure include this overview from a New York provider, available here.
